Market research
G5B.F Global Blood Therapeutics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 5B
- P/E ratio
- Not available
- Analyst target
- 72.47
- Dividend yield
- 0.0%
- Beta
- 0.43
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 5B
- P/E ratio
- Not available
- Analyst target
- 72.47
- Dividend yield
- 0.0%
- Beta
- 0.43
About
About Global Blood Therapeutics, Inc
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California. As of October 5, 2022, Global Blood Therapeutics, Inc. operates as a subsidiary of Pfizer Inc..
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the G5B.F discussion.
5 years, 5 months ago
Global Blood Therapeutics, Inc is currently in a long term downtrend where the price is trading 23.7% below its 200 day moving average.
From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 20.7.
Global Blood Therapeutics, Inc's total revenue rose by 1859.0% to $41M since the same quarter in the previous year.
Its net income has increased by 35.6% to $-62M since the same quarter in the previous year.
Finally, its free cash flow grew by 23.2% to $-50M since the same quarter in the previous year.
Based on the above factors, Global Blood Therapeutics, Inc gets an overall score of 4/5.